Day in Brief: Nifty slips 0.42% to 22,620 as pharma stumbles on a Supreme Court pricing scare, but banks rally

Two different stories, one session. Today wasn't a single narrative the way the last several sessions were. Pharma and metals fell on their own specific pressures — a fresh Supreme Court-driven regulatory scare for pharma, broader headwinds for metals — while banks, realty and media rallied on rotation, possibly aided by half-year-end portfolio positioning. The net effect was a Nifty that fell 0.42% even as the median stock on the exchange was roughly flat to higher, a genuinely different texture from Monday's uniform selloff.

The pharma story, explained. The Supreme Court raised concerns about the wide gap between what pharmacies pay manufacturers and what consumers are charged at the counter, floating the idea of a uniform framework capping retail markups at 16% above the retailer's own cost. No rule has actually been made yet — this is a court raising the question, not a regulation taking effect — but markets moved immediately to price the risk, a pattern worth remembering: regulatory scares often move stock prices well before any policy is finalized, and can just as easily fade if the court's concern doesn't turn into binding action.

• The intraday reversal was sharp: Nifty briefly tested 22,800 around 12:45 PM — a real recovery attempt — before a sharp reversal after 1:30 PM dragged it to an intraday low of 22,595. The push-and-pull suggests genuine two-way conviction today, not one-directional drift.

• Options positioning has reset for the new expiry cycle: Per the AMR, the put-call ratio fell from 0.89 to 0.79 as call writers stepped in, and the market is now pricing a roughly 275-point range (22,375-22,924) for the October 6 weekly expiry. The heaviest put open interest has moved down to the 22,000 strike, with call OI concentrated at 23,000 — a materially lower support level than the 23,000 this edition tracked as recently as Friday.

• The half-year-end flow surge is a real, if temporary, distortion: Today's FII/DII flows (₹10,148.41 crore sold, ₹11,271.73 crore bought respectively) were roughly double Tuesday's already-large figures. September 30 marks the end of the April-September half of the financial year, a period when institutional portfolio rebalancing can genuinely inflate flow numbers beyond what the underlying sentiment would suggest on its own.

• Futures positioning hasn't caught up with today's rotation: FIIs remain just 8.6% net long in index futures, unchanged from Tuesday, even as cash-market buying rotated into banks today. A futures book this bearish alongside a cash-market rally in financials is a genuine divergence worth watching over the next few sessions.

• Oil pressure continues to ease: Brent crude moderated further, trading above $90 a barrel per market commentary — a meaningful retreat from last week's roughly $108 peak, even as global cues stayed generally lacklustre.

• A quieter global backdrop than recent sessions: Unlike the Iran/Hormuz-driven volatility of the past week, today's global cues were described as lacklustre rather than actively negative — today's Indian market moves were driven far more by domestic stories (the Supreme Court pharma news, half-year-end flows) than by fresh international shocks.

• By far the largest flow day this edition has tracked: Both FII selling and DII buying roughly doubled from Tuesday's already-elevated levels — a scale consistent with half-year-end (H1 FY27) institutional portfolio rebalancing rather than a pure sentiment shift, though the two aren't mutually exclusive.

• What to watch: Whether flows normalise back toward recent levels once October trading begins, which would confirm today's spike was calendar-driven, or whether elevated two-way activity persists into next week.